Toggle Main Menu Toggle Search

Open Access padlockePrints

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

Lookup NU author(s): Professor Ruth Plummer

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 The AuthorsMucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%–20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM. KIT mutations are identified in 39/219 screened patients (18%); of 29/39 treated, 26 are evaluable for primary analysis. Six patients were alive and progression free at 6 months (local radiology review, 25%); 5/26 (19%) had objective response at 12 weeks; median OS was 7.7 months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16/17 patients. Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM. Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma. This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49).


Publication metadata

Author(s): Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S

Publication type: Article

Publication status: Published

Journal: Cell Reports Medicine

Year: 2024

Volume: 5

Issue: 3

Print publication date: 19/03/2024

Online publication date: 24/02/2024

Acceptance date: 26/01/2024

Date deposited: 26/03/2024

ISSN (electronic): 2666-3791

Publisher: Cell Press

URL: https://doi.org/10.1016/j.xcrm.2024.101435

DOI: 10.1016/j.xcrm.2024.101435

Data Access Statement: The ddPCR primer sequences are available from BioRad Assay Design Tool. De-identified data reported in this paper will be shared upon request; applicants can contact the Lead applicant of the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTU), who coordinated this study. Trial data are collected, managed, stored, shared, and archived according to ICR-CTSU Standard Operating Procedures to ensure the enduring quality, integrity, and utility of the data. Formal re quests for data sharing are considered in line with ICR-CTSU procedures with due regard given to funder and sponsor guidelines. Requests are via a standard proforma describing the nature of the proposed research and extent of data requirements. The rest of the statement is available in the published paper

PubMed id: 38417447


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
CRUK
Wellcome Trust
UK Medical Research Council

Share